United States - English - NLM (National Library of Medicine)

janssen pharmaceutical, inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - risperidone is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; stearic acid; microcrystalline cellulose; iron oxide red; hypromellose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; indigo carmine aluminium lake; lactose monohydrate; quinoline yellow; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: quinoline yellow; lactose monohydrate; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; iron oxide yellow; iron oxide red; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.